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Abstract
Background: Hepatitis E Virus (HEV) infection is a newly recognized serious threat to global public health and
Africa is suspected to be among the most severely affected regions in the world. Understanding HEV epidemiology
in Africa will expedite the implementation of evidence-based control policies aimed at preventing the spread of
HEV including policies for the use of available resources such as HEV vaccines.
Methods: Here we present a comprehensive review of HEV epidemiology in Africa based on published data. We
searched for articles on HEV epidemiology in Africa from online databases such as PubMed, Scopus, and ISI Web of
Science and critically reviewed appropriate publications to extract consistent findings, identify knowledge gaps, and
suggest future studies.
Results: Taking a particularly high toll in pregnant women and their fetuses, HEV has infected human populations
in 28 of 56 African countries. Since 1979, 17 HEV outbreaks have been reported about once every other year from
Africa causing a reported 35,300 cases with 650 deaths.
Conclusions: In Africa, HEV infection is not new, is widespread, and the number of reported outbreaks are likely a
significant underestimate. The authors suggest that this is a continent-wide public health problem that deserves
the attention of local, regional and international agencies to implement control policies that can save numerous
lives, especially those of pregnant women and their fetuses.
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Background
Hepatitis E virus (HEV) causes large outbreaks and spor-
adic cases of acute hepatitis, and an estimated one-third
of the world’s population has been infected with HEV
[1]. It is the most or second most common cause of
acute viral hepatitis among adults throughout much of
Asia, the Middle East, and Africa [2-4] although the true
burden of HEV infection remains unknown [1]. HEV in-
fection is usually self-limiting, but may develop into ful-
minant hepatitis with a case-fatality rate (CFR) between
1 and 2% in the general population [5], which can rise to
over 40% in pregnant women, especially during the third
trimester of pregnancy [6].
HEV was first identified in 1983 during the search for
the causative agent of an outbreak of enterically transmit-
ted non-A, non-B (NANB) hepatitis [7]. Its full-length
genome was first cloned in 1991 [8]. It is a spherical, non-
enveloped, single-stranded RNA virus belonging to the
Hepeviridae family and the Hepevirus genus [9]. The exist-
ing evidence suggests all human HEV strains belong to a
single serotype [10] although there are at least four geno-
types (1–4) [11,12] with 24 subtypes [3,12,13]. Genotypes
1 and 2 are predominantly found in populations in devel-
oping countries whereas genotypes 3 and 4 are zoonotic
and globally distributed [3]. Two recombinant HEV vac-
cine candidates have been clinically evaluated [14-16].
One vaccine candidate, rHEV, showed 95.5% efficacy after
three doses in phase II trial in Nepalese military popula-
tion while the other vaccine, HEV 239, showed 100%
efficacy after three doses in phase III trial in a Chinese
population. HEV 239 is licensed by China’s Ministry of
Science and Technology [17], and is being produced and
marketed by Xiamen Innovax Limited [18].
The first retrospectively (serologically) confirmed HEV
outbreak occurred in New Delhi, India in 1955–56 with
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more than 29,000 symptomatic jaundiced persons [19-21].
Since then, many serologically confirmed outbreaks and
sporadic cases [3,22] and probable outbreaks have occurred,
especially in Asia and Africa [23]. Africa has usually been
the place where resources for controlling infectious diseases
are last deployed although it is among the regions most
severely inflicted by infectious diseases [24]. Acknowledging
that understanding HEV infection and distribution in
Africa can expedite implementation of evidence-based
control policies, our overall objective was to characterize
the epidemiology of HEV in Africa by reviewing and sum-
marizing relevant, peer-reviewed literature. The authors’
specific objectives were to explore rates of infection (i.e.,
seroprevalence, outbreaks, sporadic cases), severity (i.e.,
case-fatality rates), modes of transmission, and circulating
genotypes. The authors also identified knowledge gaps in
the existing literature and suggested future studies.
Methods
Searching
We searched PubMed, Scopus, and ISI Web of Science
(up to March 24, 2014) using the following search terms:
(“Hepatitis E” OR “Non A Non B”) AND (Country_
name_1 OR Country_name_2 OR…), where ellipsis repre-
sents names of all African countries (with OR between
them) as extracted from a UN list [25]. The search term
includes “Non A Non B” because HEV was identified as
the causative agent of the enterically transmitted NANB
hepatitis [7] and thus should be responsible for at least
some of NANB outbreaks. In addition, we reviewed rele-
vant references from the articles we obtained. Articles
published in English and French were included.
Selection and methods
Figure 1 is a flow chart that describes the procedure of lit-
erature selection. We identified 219, 288, and 159 articles
from PubMed, Scopus, and ISI Web of Science, respect-
ively, and also reviewed articles obtained by screening
references. The number of articles was 426 after removing
duplicates. Of 426 articles, we synthesized 160 original
research articles that provide relevant information while
excluding the other 266 articles for the following reasons:
1. Non-African populations (n = 28)
2. Topics other than HEV epidemiology, e.g.,
molecular biology (n = 168)
3. Insufficient information, e.g., case report (n = 34)
4. Review articles (n = 25)
5. Suboptimal methodology (n = 11)
Of 160 articles, we summarized 138 articles about
serologically confirmed HEV in the main text and sep-
arately summarized NANB outbreaks in the Additional
file 1 (n = 22).
HEV seroprevalence analysis included articles describing
serology studies for total antibodies (i.e., both IgG and IgM)
or IgG to HEV by enzyme-linked immunosorbent assay,
using commercial kits or in-house methods. In outbreaks,
incident cases of HEV are defined by the existence of IgM
antibodies to HEV or paired serum samples with a signifi-
cant increase in IgG to HEV or the existence of HEV RNA
measured by reverse transcriptase polymerase chain reac-
tion. CFR was defined as the number of deaths divided by
the number of laboratory confirmed cases or cases epide-
miologically linked to HEV infections times 100.
Data source
Sources of data on the epidemiology of HEV come from (i)
seroprevalence studies in the general population (e.g., blood
donors or healthy population) or suspected high-risk popu-
lation (e.g., pig handlers or waste water treatment plant
workers or pregnant women), (ii) studies of sporadic acute
hepatitis patients, and (iii) investigations of hepatitis out-
breaks. We also discuss studies of sporadic cases and out-
breaks of NANB hepatitis viruses in the Discussion Section
with tables of data in the Additional file 1. The present
paper includes studies from 28 (50%) of 56 African coun-
tries: Algeria [26-28], Burkina Faso [29], Burundi [30,31],
Figure 1 Flow diagram for study selection.
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Cameroon [32], Central African Republic [33,34], Chad
[27,28,35-38], Côte d’Ivoire [39], Democratic Republic of
the Congo [40], Djibouti [41,42], Ethiopia [6,43], Eritrea
[44], Egypt [45-71], Gabon [72,73], Ghana [32,74-78],
Kenya [79,80], Madagascar [81], Mayotte [82], Morocco
[83-85], Namibia [86-88], Nigeria [89-91], Senegal [92,93],
Somalia [94-96], South Africa [97,98], South Sudan [99],
Sudan [35,100-105], Tunisia [106-111], the United Republic
of Tanzania [112-114], and Zambia [115].
Results
Seroprevalence of anti-HEV antibodies
Data on seroprevalence of anti-HEV antibodies comes
from 35 studies in 13 African countries. Table 1 presents
a summary sorted by country name and seroprevalence.
Seroprevalence varies by country from 84.3% [55] among
pregnant Egyptian women aged 24 years on average to
0% among village residents aged 24 years on average in
Gabon [72]. The seroprevalence seems to be higher in preg-
nant women than in the general population in Ghana
(28.7% [78] vs. 4.6% [76]) and also in Gabon (14.2% [73] vs.
0% [72]). Two studies of Ghanaians suggest that predomin-
ant HEV genotypes in that country may be of zoonotic ori-
gin: seroprevalence among pig handlers is over 34% [75,77]
whereas that among general population is about 4% [76].
Seroprevalence also differs between rural and urban areas.
In Gabon, one study found a higher prevalence of HEV of
about 2.0 times in urban (13.5%) compared with rural areas
(6.4%) [73]. On the other hand, in South Africa, HEV sero-
prevalence is higher in rural compared with urban residents
(15.3% vs. 6.6%) [98]. The difference in seroprevalence
between rural and urban residents is also observed in Egypt
with seroprevalence being higher in rural areas [53].
Sporadic hepatitis cases attributed to HEV
Data on acute hepatitis E come from studies of sporadic
acute hepatitis cases and are available from 29 studies in
13 African countries. Table 2 shows a summary sorted by
country followed by decreasing proportion of sporadic
hepatitis cases that are attributable to HEV infection.
Table 2 also provides characteristics of sporadic hepatitis
cases studied and types of antibodies tested (i.e., IgG or
IgM). The proportion of cases that are attributable to
HEV ranges from 70% in male patients aged 25–33 years
in Nigeria [89] to 2% in patients aged < 15 years in Egypt
[48]. It is interesting to note that existing studies show that
the proportions of cases that are attributable to HEV
are lower than 27% in Egypt despite their high HEV
seroprevalence: the majority of acute hepatitis patients
were attributable to HAV [45,48,64,70] or HBV [71]. For
example, one study of acute hepatitis among Egyptian
children with a mean age of 5.4 years reported that HAV
was responsible for 35 out of 36 acute hepatitis cases
whereas HEV was detected in only one case [48].
Outbreaks and attack rate
The first well-characterized outbreak of laboratory-
confirmed Hepatitis E occurred in Côte d’Ivoire in
1986 [39]. However, assuming that hepatitis outbreaks
characterized by acute jaundice and a high CFR among
pregnant women were likely due to HEV, Teo identi-
fied earlier, probable HEV outbreaks in Tunisia from
1950 to 1953, Algeria from 1952 to 1956, Congo in
1958, Morocco from 1958 to 60, and Libya from 1968
to 1970 and also in 1975 [23].
HEV outbreaks have been detected in 11 African
countries (17 studies), of which some outbreaks in
refugee camps [79,86,100] and Table 3 presents a sum-
mary of these outbreaks sorted by country name and
decreasing clinical attack rate. The highest attack rate
(25.1%) of the population was observed during out-
breaks in two subcounties of Kitgum District, Uganda
from October 2007 to June 2009 [119,120]. Attack rate
could have been even higher because the epidemic had
not ended at the time of the investigation and in
particular, it had not even peaked but was increasing in
one of two subcounties. The lowest attack rate (2.7%) was
observed during an outbreak in the Central African
Republic on July 2002 [34].
Published reports suggest clinical HEV infection risk is
highest among young adults in African populations
[44,79,86,94,100,119,120] although one study reports no
significant difference in the risk of clinical HEV infec-
tion by age [34]. Studies show mixed results regarding
whether sex predisposes people to clinical HEV infection
(i.e., higher risk for males [86] or higher risk for females
[119,120] or no significant difference [34,79,94,100,123].
Case fatality rate (CFR)
The CFR from outbreak investigations or sporadic cases
were reported by 8 African countries (10 studies). Table 4
presents a summary sorted by CFR and pregnancy. CFR’s
in the overall population range from 17.8% in Darfur,
Sudan in 2004 [101] to 1.5% in Uganda during March to
December, 2008 [123]. Among pregnant women, fatalities
are considerably higher ranging from 42.1% among spor-
adic cases sampled during 1988-91in Ethiopia [6] to 12.5%
during an outbreak in Dadaab refugee camp of Kenya in
2012 [80]. Compared with the overall population, fatalities
are also higher in children under 2 years of age. One study
in Uganda using active case detection and verbal autopsies
found that icteric children less than two years of age expe-
rienced 13% mortality, which was higher than the 6.9%
experienced among pregnant woman [120]. One author
claims that the inoculum size may be important in deter-
mining CFR: CFR was 8.6% among villagers supplied by
wells whereas it was 2.5% and 0.8% in those relying on
river and pond water, respectively [94].
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Table 1 Seroprevalence of anti-HEV antibodies in Africa







Burkina Faso 19.1 Blood donors 178 2010-12 IgG [29]
11.6 Pregnant women 189 2010-12 IgG [29]
Burundi 14.0 Adults without chronic liver disease, 44.7 yrs old (±13.5) 129 1986 Total Ig [30]
Cameroon 14.2 HIV-infected adults, 38.1 yrs old (±11.3) 289 2009-10 IgG [32]
2.0 HIV-infected children, 8.3 yrs old (±7.5) 100 2009-10 IgG [32]
CARa 24.2 Patients attending the center for sexually transmitted diseases 157 1995b Total Ig [33]
Djibouti 13.0 Male peacekeepers in Haiti, 31.2 yrs old 112 1998b Total Ig [42]
Egypt 84.3 Pregnant women, 24 yrs old (16–48) 2,428 1997-2003 Total Ig [55]
80.1 Patients with chronic liver disease, 48 yrs old (23–62) 518 2000-2 IgG [57]
67.6 Residents of two rural villages, 24.5 and 26.5 yrs, respectively 10,156 1997 Total Ig [54]
58.6 Pregnant women, ~33 yrs old 116 2009 IgG [58]
56.4 Residents of a semi-urban village, 1–67 yrs old 140 1993 Total Ig [51]
51.2 Waste water treatment plant workers, 47.1 yrs old 43 2011b Total Ig [60]
50.6 Waste water treatment plant workers, 20–60 yrs old 233 2000b Total Ig [61]
45.3 Blood donors, 18–45 yrs old 95 1998b IgG [52]
54.1 Four waste water treatment plant male workers, 20–60 yrs old 205 1998-9 IgG [116]
39.6 Haemodialysis patients, 8–20 yrs old 96 1998b IgG [52]
38.9 Healthy females, 21.8 yrs old (16–25) 95 1995 IgG [50]
17.2 Residents of a hamlet, 20.9 yrs old (<1-95) 1259 1992 IgG [49]
0.0 Healthy controls, 20–60 yrs old 96 1998-9 IgG [116]
Gabon 14.2 Pregnant women, 24.6 yrs old (14–44) 840 2005, 2007 IgG [73]
0.0 Villagers, 29 yrs old (2–80) 35 1991-2 Total Ig [72]
Ghana 45.3 Adult HIV patients (n = 402), 40 yrs old (±9.6) 402 2008-10 IgG [32]
38.1 Pig handlers, 36.5 yrs old (12–65) 105 2009b Total Ig [77]
34.8 Pig handlers, 32.9 yrs old (15–70) 353 2008 Total Ig [75]
28.7 Pregnant women, 28.9 yrs old (13–42) 157 2008 Total Ig [78]
4.6 Blood donors 239 2012b IgG [76]
4.4 6-18 yr olds 803 1993 Total Ig [74]
Madagascar 14.1 Slaughterhouse workers 427 2008-9 Total Ig [81]
Morocco 8.5 Blood donors 200 2000-1 IgG [85]
2.2 232 men and 259 women, 27.7 yrs old (±5.9) 491 1995b IgG [84]
Nigeria 43.0 Health care workers 88 2008-9 Total Ig [90]
94.0 Control healthy adults 44 2008-9 Total Ig [90]
13.4 Healthy and sick people, 29.8 yrs old (3–72) 186 2007 Total Ig [91]
South Africa 10.7 Urban (n = 407) and rural (n = 360) blacks, 42.4 yrs old (18–85) 767 1996b Total Ig [98,117]
2.6 Medical students 227 1992 Total Ig [97]
1.8 Canoeists who have been regularly exposed to waste water 555 1992 Total Ig [97]
Tanzania 6.6 Women, 32.1 yrs old (15–45) 212 1996 Total Ig [114]
0.2 Healthy adults, 30.3 yrs old 403 1992 Total Ig [112]
0.0 Women, 24.5 yrs old 180 1995 Total Ig [113]
Tunisia 46.0 Healthy persons, > 60 yrs old 100 1991 IgG [106]
29.5 Children with chronic haematological diseases 34 1996 IgG [106]
28.9 Polytransfused patients; adults (n = 59, 34.8 yrs old (20–61))
and children (n = 48, 7.3 yrs old (1–15))
107 2008-9 IgG [107]
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Genotype prevalence
Data on the genotypes of circulating HEV’s are available
for 9 countries (16 studies). Table 5 presents a summary
sorted by genotype and also provides characteristics of the
sample, genomic regions tested. Genotype 1 seems to be
most prevalent as it was found in Central African Republic
[34], Sudan [35], Chad [28,35], Egypt [46,62,124], and
Namibia [88] followed by genotype 2, which were ob-
served in Central African Republic [34], Chad [35],
Namibia [87], and Nigeria [6,89]. Genotype 3 is rare and
was found in one Egyptian child [48], one acute hepatitis
patient in Mayotte (originally from France) [82]. Genotype
prevalence can differ in neighboring countries as was
demonstrated by one study in Sudan and Chad where
genotype 1 was more common in Sudan and genotype 2
was more common in Chad [35], Figure 2 shows a map of
Africa where countries in which HEV infections were ob-
served are differently colored according to HEV genotype.
Mode of transmission
Studies stress the importance of fecal contamination of
water as a main source of infection in outbreaks across
African countries [34,44,86,94,100,101,123]. However, in a
laboratory-confirmed HEV outbreak of 3,218 cases in
northern Uganda, the authors suggest that some patients
were infected through person-to-person transmission,
which is supported by three observations: (1) HEV was
not detected from water or zoonotic sources, (2) the epi-
demic curve suggested a propagated, not point-source
outbreak, and (3) there was evidence of close contact be-
tween incident cases and subsequently infected household
contacts after an incubation period [120]. Non-human
reservoirs have been identified in donkeys in Sudan (un-
known genotype) [100] and pigs the Democratic Republic
of the Congo and Uganda (both genotype 3), and cows,
buffaloes, sheep and goats in Egypt [40,120]. In Ghana,
the high prevalence (34.8%) of antibodies to HEV in pig
farm workers was reported with the greatest risk factor
being close contact with piped-water [75,77]. No data have
been reported from Africa suggesting the transmission of
HEV by transfusion or by sexual intercourse [125] al-
though the transmission of HEV by transfusion has been
well documented in Europe and Japan [126,127]. A single
Egyptian study suggested HEV transmission from mothers
to their neonates. Of nine mothers PCR positive for HEV
RNA, five (55.6%) of their neonates were also PCR positive
[128]. No other studies have investigated mother-to-child
transmission in Africa.
Co-infection with other infectious diseases
Three infectious diseases—hepatitis viruses other than
HEV, schistosomiasis, and HIV—are known to be associ-
ated with an increased risk or severity of HEV infection
from published studies. First, infection with other hepatitis
viruses was positively associated with infection with HEV.
One study found a high prevalence of anti-HEV antibodies
in Egyptian children infected with Hepatitis B (56.7%),
Hepatitis C (52%) and both Hepatitis B and C (30%) com-
pared with patients with non-A, non-B, non-C hepatitis
(7.1%) [129]. Second, one study showed that patients with
schistosomiasis infection had a higher prevalence of HEV
infection: seroprevalence of HEV infection was 31% in
patients with Schistosoma mansoni whereas it was 14%
among parasite-free individuals [53]. Third, studies re-
ported discordant findings as to whether patients with
HIV infection or AIDS are at increased risk for HEV infec-
tion. One study reported that anti-HEV seroprevalence
among HIV/AIDS cases in Africa was similar to HIV neg-
atives and concluded that there is no significant increased
risk for HEV infection in patients with HIV positive [30].
Another study showed the seroprevalence of anti-HEV
IgG antibodies was higher among HIV-1 infected women
than HTLV-I infected women (7.1% vs. 5.0%) [130]. Simi-
larly, HEV infection was significantly more common in
HIV-seropositive than HIV-seronegative Zambian adults
(odds ratio = 6.2, 95% CI, 2.2-17.8). [115]
Discussion
The first documented outbreak of HEV infection likely oc-
curred in 1950 in Tunisia [23] and since the 1980’s, when
Table 1 Seroprevalence of anti-HEV antibodies in Africa (Continued)
22.0 Healthy blood donors, < 40 yrs old 100 1996 IgG [106]
12.1 Pregnant women, 30.1 yrs old (17–52) 404 2008-9 IgG [108]
10.0 Healthy controls; blood donors (n = 100, 31.3 yrs old (20–58))
and children, (n = 60, 7.9 yrs old (1–15))
160 2008-9 IgG [107]
5.4 Blood donors, 32.6 yrs old (±8.6) 687 2007-8 Total Ig [109]
4.3 Healthy persons, 20.7 yrs old (16–25) 1,505 2008b IgG [110]
Zambia 42 Urban adults, 18–64 yrs old 106 1999 IgG [115]
16 Urban children, 1–15 yrs old 194 2011 IgG [115]
aCAR; Central African Republic.
bThe year of the publication.
Seroprevalence varies by country and by subpopulation and studies were done under different conditions (e.g., sample size, demographics, and different
diagnostic methods). Age of the sample is provided as mean (range or ± standard deviation, if available).
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HEV diagnostic assays became available, half of all African
countries including nations in north, south, east, west, and
central Africa have published articles of Hepatitis E infec-
tions. Clearly, these results suggest that HEV infection is
not new to Africa and implies that this is a continent-wide
public health problem and a potential threat to travelers.
This is supported by a recently published study on HEV in
low- and middle-income countries in Asia and Africa [131].
HEV infection deserves the attention of local, regional and
international agencies.
Since nations lack routine surveillance for HEV infec-
tion, it is difficult to estimate the African disease burden.
However, these publications suggest that outbreaks are
frequent with about one outbreak report published every
other year from Africa. As only a few outbreaks are likely
identified and even fewer reported in peer-reviewed jour-
nals, it is probable that outbreaks in Africa are even more
common than these reports imply. To address HEV out-
break control, routine HEV surveillance and response is
necessary and could be integrated with measles or polio-
myelitis surveillance, which are ongoing activities in most
countries.
Among HEV outbreaks, the overall case-fatality rate is
comparable to that seen with other diseases such as cholera
Table 2 Sporadic cases caused by hepatitis E virus in Africa







Chad 48.8 Acute or fulminant hepatitis patients, 4–64 yrs old 41 1993 IgM [36]
20.0a Sporadic cases 17 1994 RT-PCRb [27]
Djibouti 58.5 Acute hepatitis patients, 21 · 8 yrs old (2–65) 65 1992-3 IgM [41]
Egypt 21.7 Acute hepatitis patients, 26 · 6 yrs old (18–60) 143 1993-4 IgM [71]
24.2 Jaundiced patients, 1–73 yrs old 202 1993 IgM [46]
22.2 Jaundiced children, 5 yrs old (1–11) 261 1990 IgM [70]
20.2 Acute viral hepatitis patients, 8 yrs old 287 2006-8 IgM [62]
17.9 Acute hepatitis patients, 15.7 (± 14.9) yrs old 235 2007-8 IgM or > =3-fold rise in
IgG
[69]
17.2 Children with elevated level (two-fold or more) of AST and
ALT
64 2006d IgM [47]
15.7 Acute hepatitis patients, 15.9 yrs old (1–65) 235 2007-8 IgM [63]
15.1 Children with acute jaundice, 6 · 4 yrs old (1–13) 73 1987-8 IgM [45]
12.5 Patients with acute hepatitis, 20 · 2 yrs old (4–65) 200 2001-2 IgM [64]
6.0 Children with minor hepatic ailments, 6 mo −10 yrs 100 2004-5 IgM [65]
5 · 0 Patients with acute on chronic liver failure, 46.4 yrs old 100 2009-10 IgM [66]
2.1 Acute viral hepatitis patients, 25 yrs old (2–77) 47 2002-5 IgM [67]
2.0 Hepatitis patients, 5.4 yrs old (1.5-15) 50 2007 RT-PCR [48]
Ethiopia 45.6 Acute viral hepatitis patients with NANB 79 1988-91 FABAd [43]
31.8 Non-pregnant women with acute viral hepatitis, 30 yrs old 22 1988-91 FABA [6]
67 · 9 Pregnant women with acute viral hepatitis, 26 yrs old 28 1988-91 FABA [6]
Mayotte 100.0 Patients with acute jaundice, 46 yrs old 1 2009 IgM [82]
Nigeria 70.0 Male patients with acute hepatitis, 25–33 yrs old 10 1997-8 RT-PCR [89]
Senegal 20.0 Patients with jaundice 30 1992c IgM [93]
10.2 Patients with viral hepatitis 49 1993c IgM [92]
Somalia 61.1 Native Somalis and displaced Ethiopian patients
with acute hepatitis, 7–90 yrs old
36 1992-3 IgM [96]
Sudan 5.4 Patients with fulminant hepatic failure, 38 yrs old (19–75) 37 2003-4 IgM [103]
59.0 Children with acute clinical jaundice, ≤14 yrs old 39 1987-8 IgM [118]
a20% was extrapolated from the results of RT-PCR results of 5 samples out of total 17 cases.
bReverse transcription polymerase chain reaction.
cThe year of the publication.
dFABA; fluorescent antibody blocking assay, which is claimed to detect acute infection, not but past infection.
Proportion of sporadic hepatitis cases attributable to HEV varies by country and by subpopulation and studies were done under different conditions (e.g., sample
size, demographics, and different diagnostic methods). Age of the sample is provided as mean (range or ± standard deviation, if available).
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Table 3 Hepatitis E outbreaks in Africa




Variance in clinical attack rates Source
By age By gender
Algeria 1979-80 20 NAa NA NA [27]
CARb Jul - Oct 2002 715 2.7% No significant difference No significant difference [34]
Jun 2004 - Sep 2005 411 NA The age group 18–34 years was more frequently
anti-HEV IgM positive (91.2%) than those aged
1–17 (78.0%) or over 34 (64.9%) (p < 0.001)
Risk for infection was clearly higher in males
than females based on IgG seroprevalence
(OR = 2.04; 95% CI 1.21-3.45; p < 0.005)
[121]
Chad 1983-4 34 NA NA NA [27]
Jun - Aug 2004 989 (30) NA NA NA [37,38]
Djibouti Dec1992-Sep1993 43 NA NA NA [41]
Eritrea Oct 1988-Mar 1989 > 750 NA 81% of the patients were between 18 and
30 years of age among aged from 15 to 56.
The outbreak among military personnel;
no female patients
[44]
Kenyad Mar - Oct 1991 1,765 (63) 6.3% (n = 26,920) Increased with age with a peak among those >30,
while serologic attack rate is not different by age group
Clinical attack rate is 6.1% for male
and 6.3% for female
[79]
Jul - Nov 2012 349 (10) NA NA 184 (54.3%) were females. [80]
Morocco 1994 > 75 NA NA NA [83]
Namibiad Jul - Oct 1983 201 NA Most common in persons aged 25–29 years old
among patients aged 5–54 years old
72% of 64 patients were male. [86]
Somalia 1988 – 9, 23 months 11,759 (346) 4.7% (n = 245,312) Increased with age groups: 5%, 13%, and 20% for
those aged 0–4, 5–15, and >15 years old, respectively
Female-to-male ratio was 1.08:1 [94,95]
South Sudan Jul 2012-Jan 2013 5,080 7.4% Persons aged 18–59 years had the highest attack rates NA [99]
Sudan Oct 1988 ≥55 NA NA NA [122]
Jul - Dec 2004 2,621 (45) 3.3%c,d (n = 78,800) Being 15–45 years old was a risk factor for
clinical HEV infection with odds ratio being
2.13 (95% CI, 1.02-4.46).
No significant difference [100]
Nov 2010-Mar 2011 39 e (11e) NA NA Only pregnant women were reported. [104]
Uganda Oct 2007 -Jun 2009 >10,356 (160) 25.1% (n = 19,098) < 2 year olds (6.9%) vs. pregnant women (87%) 22% males vs. 28% females (p < 0.001) [119,120,123]
aNA; not available.
bCAR; Central African Republic.
cActive case finding suggested a clinical attack rate of 16%.




















and measles signifying that these patients require equal
attention. Like HEV infections among pregnant woman in
Asia, the clinical prognosis is far worse for pregnant women
than for men with fatalities reaching four out of 10 infected
pregnant women [6]. The concerns for pregnant woman
are further amplified when recognizing that HIV prevalence
is high among pregnant women in sub-Saharan Africa
[132] and co-infection with HIV and HEV as reported here
may increase the risk of fulminant or chronic hepatitis.
African men co-infected with HIV and HEV are similarly at
risk of complications. While appreciating the hardship from
all HEV-associated deaths, maternal deaths are the great
tragedy of HEV infection likely causing serious adverse
consequences for the health and well-being of surviving
family members, especially children.
It has been suggested that many hepatitis outbreaks that
occurred before the development of diagnostic assays for
any hepatitis virus and enterically transmitted NANB
hepatitis outbreaks were likely due to HEV as CFRs in
pregnant women in these outbreaks were disproportion-
ately high and attack rates were higher in young adults
compared to children or adults [23]. This review supports
the prior study showing that outbreaks and sporadic cases
by NANB reported in Africa, many of which were not
considered in the previous study, also display high CFR in
pregnant women and high clinical attack rate among
young adults (Tables A1-A3 in the Additional file 1).
We noted several limitations with the existing literature.
First, there is no diagnostic “gold standard” for HEV infec-
tion and existing studies use different assays that vary in
sensitivity and specificity adversely impacting the validity
and comparability of reports. Second, studies measure the
prevalence of HEV infection in dissimilar subpopulations
making it difficult to compare seroprevalence. For example,
it is difficult to conclude whether the overall seroprevalence
Table 4 Case-fatality rates (CFRs) of HEV infection
Country Year Case-fatality rate (n = no. of cases) Source
Pregnant female Overall
CARa 2002 20% (n = 5) 1.8% (n = 222) [34]
Chad 2004 NAb 3.0% (n = 989) [37]
Eritrea 1988-89 NA 0% (n = 423) [44]
Ethiopia 1988-91 42.1% (n = 19) NA [6]
Kenya 2012 12.5% (n = 72) 2.9% (n = 339) [80]
Somalia 1988-9 13.8% (n = NA) 3.0% (n = 11,413) [94]
South Sudan 2012-3 10.4% (n = 211) NA [99]
Sudan 2004 31.1% (n = 61) 17.8% (n = 253) [101]
2004 31.1% (n = 61) 1.7% (n = 2,621) [100]
2004 NA 1.7% (n = 2,472) [37]
Uganda 2008 NA 1.5% (n = 9,648) [123]
aCAR; Central African Republic.
bNA; not available.
Table 5 Genotype distribution from African HEVs
Genotype Country Year of sampling Sample RNA region tested Source
1 CARa 2002 One fecal sample from an outbreak NAb [34]
Chad 1984 A patient with hepatitis E Complete genome [28]
2004 Five isolates from an outbreak ORFc2 (363 ntd) [35]
Egypt 1993 Acute hepatitis patients ORF1 (location: 55–320) [46]
2006-8 Acute hepatitis patients ORF1 [62]
2012e Sixteen isolates from acute hepatitis patients ORF2 (189 nt) [124]
Namibia 1983 Nine isolates from an outbreak in Kavango ORF2 (296 nt), 3 (188 nt) [88]
Sudan 2004 Twenty three isolates from an outbreak ORF2 (363 nt) [35]
Uganda 2007 Internally displaced persons camp NA [123]
2008 Twenty four isolates from an outbreak NA [119]
2 CAR 2002 Three fecal samples from an outbreak NA [34]
Chad 2004 Four isolates from an outbreak ORF2 (363 nt) [35]
Namibia 1995 Four isolates from NANB outbreak in Rundu ORF2 (451 nt near 3’-end) [87]
Nigeria 2000e Ten adult acute hepatitis patients ORF1, 2 (3’-end) [89]
3 Egypt 2007 One 9 year-old acute hepatitis patient ORF1, 2, 2/3 [48]
Mayotte 2009 One French acute hepatitis patient (46 yr old) ORF2 (288 nt) [82]
Madagascar 2008-9 Slaughter house workers ORF2,3 (1000 nt) [81]
aCAR; Central African Republic.
bNA; not available.
cORF; open reading frame.
dnt; nucleotides.
ePublication year.
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of HEV infection in South Africa is higher than that in
Morocco when examining studies that show seroprevalence
among South Africans with a mean age of 42 years is 10.7%
[98] and that among younger population in Morocco is 2.2-
6.8% [84,85]. Third, studies use different criteria to define
acute hepatitis. In a study of Egyptian children, acute hepa-
titis was defined as the acute injury to the liver, manifested
by two fold or more increase in the level of aspartate ami-
notransferase and alanine aminotransferase [47] whereas in
another study, acute hepatitis was defined as the patient
whose aminotransferase level was 5 times the normal value
[133]. Finally, different surveillance methods may lead to
different attack rates being determined. Attack rates are
exceptionally difficult to determine in un-enumerated
populations, which is likely to be the case in many African
nations. The limitations noted above could be corrected in
future studies by developing and publishing standardized
study methods including case definitions and analytical
plans and by development of a generic protocol for out-
break and endemic disease investigations. For diagnosis,
an enzyme-linked immunosorbent assay for HEV IgG and
IgM (Beijing Wantai Biological Pharmacy Enterprise CO.,
LTD.) shows high sensitivity and specificity compared to
other assays including molecular methods [134].
There are knowledge gaps. Serology studies suggest that
many Africans are infected with HEV, but except during
outbreaks, symptomatic disease is only sporadic implying
that case finding is incomplete or that only a few infected
cases progress to clinical disease. Pathogenesis studies are
needed. While there are a growing number of published
reports on the impact of HEV infection, the overall burden
of hepatitis E in Africa remains unclear. For example, two
studies from South Asia using verbal autopsies suggest
that HEV is responsible for 10% or more of pregnancy-
associated deaths [135,136]. The same investigation should
also be carried out in multiple sites in Africa. HEV trans-
mission in nations with genotypes 1 and 2 likely occurs
from the fecal-oral route. However, the authors in one
study on the HEV epidemic in Uganda during 2007–9
claimed that person-to-person transmission played a sig-
nificant role in the propagation of HEV [120,137]. Because
of the implications for control measures, this report im-
plies that HEV transmission studies should be carried out.
Given the high background rates of HEV infection, the ef-
fect of co-infections (e.g., HIV, Hepatitis B) on the severity
of disease especially in pregnant women are needed. Po-
tential risk factors for HEV infection such as co-infections
or pregnancy need to be clarified. Studies of vertical trans-
mission and blood donor screening should be funded.
As these results suggest that acute hepatitis E is fecal-
orally transmitted in African countries, the ultimate control
of this disease will require increased access to safe water
and sanitation and improved personal hygiene. Until these
measures are universal, an anti-HEV vaccine is needed.
Hecolin™ is a safe and effective anti-HEV vaccine for
healthy subjects 16 years of age and older exposed to HEV
genotype 4. The vaccine is now licensed in China [14]. This
vaccine shows promise for outbreak interventions and con-
trol of endemic disease but several epidemiological issues
need to be addressed before the vaccine is used widely in
Africa. The participants in the efficacy trial used for licens-
ing Hecolin™ were healthy adults, and there is no safety
Figure 2 Map of Africa. Colored areas represent countries where HEV is endemic at least for some subpopulations or sporadic HEV cases or
outbreaks have been detected. Circles indicate HEV outbreaks with centers and areas indicating the location and outbreak size, respectively.
Different colors represent different genotypes. White areas indicate countries where no data is available.
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data on persons with chronic liver disease, the immuno-
compromised, and among children less than 16 years old.
While the vaccine has also been found safe in a small num-
ber of pregnant women (n = 37) inadvertently vaccinated
during a large clinical trial [138], there is a necessity for
demonstrating safety in well-powered trials of pregnant
women as this population should be included in outbreak
response because of the high case fatality rate. While vac-
cine efficacy has been established for genotype 4, there are
no studies in patients with genotype 1 or 2, the prominent
strains in Africa. For outbreaks, it is unknown how quickly
after the first injection protection will be afforded to those
at risk early in the outbreak. There are no published reports
on the length of protection. Still, these issues can and
should be addressed quickly as there is a potential for this
vaccine is be a major component of African HEV control
program.
Conclusions
Extensive data suggest that hepatitis E is a major contribu-
tor to disease and mortality across much of the African
continent, with country-level variability, as expected. Still, it
is challenging to make comparisons across these popula-
tions, given differing methodologies and assays used to
determine HEV etiology. Despite its substantial impact on
human health, HEV has, even in hyper-endemic South
Asia, been neglected in recognition as a major public health
problem since its identification. Given the emerging evi-
dence that HEV could be vaccine preventable, we hope this
review will shed light on a pathogen of significance across
the African continent.
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